Drugs / HSK39775
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06314373 | Mar 2024 → Feb 2028 expected | cancer | Xizang Haisco Pharmaceutical Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HSK39775 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06314373 ↗ |
| Route | Oral | “HSK39775 will be administered orally once daily” NCT06314373 ↗ |